-+ 0.00%
-+ 0.00%
-+ 0.00%

Enliven Therapeutics to present Phase 1 ENABLE trial data for ELVN-001 in CP-CML at SOHO 2026

PUBT·08/31/2026 22:05:22
Listen to the news
Enliven Therapeutics to present Phase 1 ENABLE trial data for ELVN-001 in CP-CML at SOHO 2026
  • Enliven Therapeutics scheduled an encore data presentation from its ENABLE Phase 1 trial of ELVN-001 at SOHO 2026.
  • Results were previously presented at the European Hematology Association 2026 Congress.
  • SOHO oral session set for Sept. 10, 2026; poster session set for Sept. 9, 2026, in Houston.
  • Trial evaluates ELVN-001 in previously treated chronic-phase CML, including patients with T315I mutations and those resistant or intolerant to TKIs.
  • Update centers on safety, tolerability, drug exposure, and signs of clinical activity to support dose selection for further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608311805PR_NEWS_USPR_____LA36478) on August 31, 2026, and is solely responsible for the information contained therein.